| Name | Company | P/L % | MPV |
|
|---|---|---|---|---|
| Lord Glendonbrook |
|
Stryker / NYQ:SYK | 427.15% | £369,007.51 |
| Lord Glendonbrook |
|
Abbott Laboratories / NYQ:ABT | 395.88% | £347,114.98 |
| Lord Sassoon |
|
Abbott Laboratories / NYQ:ABT | 280.82% | £266,574.45 |
| Lord Grabiner |
|
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
| Baroness Noakes |
|
Smith & Nephew / NYQ:SNN | 57.10% | £109,969.34 |
| Lord Glendonbrook |
|
Smith & Nephew / NYQ:SNN | 45.81% | £102,065.72 |
| Lord Mance |
|
Stryker / NYQ:SYK | 33.07% | £93,150.91 |
| Lord Londesborough |
|
Abbott Laboratories / NYQ:ABT | 15.14% | £80,594.56 |
| Lord Glendonbrook |
|
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
| Lord Howard of Rising |
|
Ekf Diagnostics / LSE:EKF.L | -4.04% | £67,172.59 |
| Lord Glendonbrook |
|
Align Technology / NMS:ALGN | -43.38% | £39,634.70 |
| Lord Browne of Madingley | Allurion / NYQ:ALUR | -51.96% | £33,625.38 | |
| Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** |